iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
Outcomes of Patients Interrupting Glecaprevir/Pibrentasvir Treatment: A Case Series From Clinical Trials
  Philippe Zamor1, John Dillon2, Douglas Dylla3, David Mutimer4, Reem Ghalib5, Massimo Colombo6, Richard Skoien7, Eric Crown3, Yiran Hu3, Eric Lawitz81Division of Hepatology, Carolinas Healthcare Systems, Charlotte, North Carolina, United States; 2Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, United Kingdom; 3AbbVie Inc., North Chicago, Illinois, United States; 4NIHR Liver Biomedical Research Unit, University of Birmingham, Birmingham, United Kingdom; 5Texas Clinical Research Institute, Arlington, Texas, United States; 6Center for Translational Hepatology Research, Clinical and Research Center Humanitas Hospital, Rozzano, Italy; 7Hepatic Fibrosis Laboratory, QIMR Berghofer Medical Research Institute, Queensland, Australia; School of Medicine, University of Queensland, Queensland, Australia; Department of Gastroenterology and Hepatology, Royal Brisbane and Women’s Hospital, Queensland, Australia; 8The Texas Liver Institute, University of Texas Health San Antonio, San Antonio, Texas, United States
Hep Dart 2019, December 8-12,
2019, Kauai, Hawaii
Reported by Jules Levin








  iconpaperstack View Older Articles   Back to Top   www.natap.org